Cas:1065074-00-1 N-Cyclohexyl 3-bromo-4-fluorobenzamide manufacturer & supplier

Chemical Name:N-Cyclohexyl 3-bromo-4-fluorobenzamide

CAS.NO:1065074-00-1

Synonyms:3-Bromo-N-cyclohexyl-4-fluorobenzamide

Molecular Formula:C₁₃H₁₅BrFNO

Molecular Weight:300.16700

HS Code:2924299090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:29.10000

Exact Mass:299.03200

LogP:4.04160

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 3-Bromo-N-cyclohexyl-4-fluorobenzamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-Bromo-N-cyclohexyl-4-fluorobenzamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-Bromo-N-cyclohexyl-4-fluorobenzamide Use and application,3-Bromo-N-cyclohexyl-4-fluorobenzamide technical grade,usp/ep/jp grade.

Related News: Beta Bionics is pursuing regulatory approval of its insulin-only bionic pancreas, followed by its dual-hormone system, which will also administer a glucagon analog in order to raise blood-sugar levels without the need to consume carbohydrates. Beta Bionics operates in Massachusetts and California. N-Cyclohexyl 3-bromo-4-fluorobenzamide manufacturer Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2). N-Cyclohexyl 3-bromo-4-fluorobenzamide supplier INSPIRE is a global, multi-center, randomized, controlled study to assess the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients who had progressed on, failed to respond to, or relapsed after previous treatment with a hypomethylating agent (HMA) within nine cycles over the course of one year after initiation of HMA treatment. N-Cyclohexyl 3-bromo-4-fluorobenzamide vendor The glucagon-only configuration may be helpful in rare conditions that often lead to chronic, low blood-sugar conditions, such as congenital hyperinsulinism (CHI). N-Cyclohexyl 3-bromo-4-fluorobenzamide factory At ASH, scientists from the Company and MSK presented new in vivo preclinical data demonstrating that FT819 exhibits durable tumor control and extended survival.